What is CKD and why is MATLOC important?

Chronic Kidney Disease (CKD) is one of the most common diseases in the world, yet it often goes unnoticed. This is due to silent disease symptoms and poor screening methods, which leave 9/10 people who have CKD not knowing they have it and over 50% of the high-risk US population not receiving adequate testing. Due to the prevalence of diabetes and hypertension in, which make up 2/3rds of all CKD cases, there are over over 120 million high-risk patients.

This means over 60 million high-risk patients are not receiving proper testing and means too many individuals ending up with end-stage renal disease (ESRD) outcomes like kidney failure, dialysis, and transplant. These ESRD outcomes make up 1% of the Medicare population while being responsible for 7% of the budget. In total, Medicare spends 24% of its budget, or over $130B, on kidney disease annually.

With a push towards preventative care in the US, MATLOC aims to remove the barriers of CKD testing by creating accessible and affordable, point-of-care, lab-equivalent technologies.